Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancers|May 13, 2023
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint InhibitorsDirk Tomsitz, Theresa Ruf, Sarah Zierold, et al.
Journal of the American Heart Association|March 5, 2021
Brain-Derived Neurotrophic Factor Expression and Signaling in Different Perivascular Adipose Tissue Depots of Patients With Coronary Artery DiseaseSarah Zierold, Katja Buschmann, Sogol Gachkar, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 14, 2024
Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective StudyTheresa Ruf, Farnaz Rahimi, David Anz, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2022
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of lifeThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
Cancer Immunology, Immunotherapy : CII|May 16, 2022
Checkpoint-inhibitor induced Polyserositis with EdemaSarah Zierold, Larissa Semra Akcetin, Eva Gresser, et al.
JAAD International|June 17, 2024
Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression levelBarbara Meier-Schiesser, Christine Zecha, Sarah Zierold, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitorsTheresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort studyLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Pageof 2